The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest ... the drugmaker says on its web site. “If you have commercial drug insurance with coverage for Zepbound ...

(Reuters) -Eli Lilly's obesity drug Zepbound can now be covered ... for a secondary use by the Food and Drug Administration. Commercial insurers and employers were previously hesitant to cover ...

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

Since commercial insulin ... Novo Nordisk and Eli Lilly are both excellent companies. The former has world leadership in products against obesity and diabetes, the latter in recent years has ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

but is now facing a strong challenge from Eli Lilly. The US pharma has just reported top-line results from the first phase 3 trial of its dual GLP-1/GIP agonist tirzepatide as an obesity therapy ...

Commercial insurers and employers ... to reduce the risk of heart attacks and strokes. Lilly and Novo are testing their blockbuster obesity drugs for a range of conditions as they race to ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

The company's head of obesity said the ultimate goal is to develop a once-per-year shot. Imagine this: You walk into your doctor and get your yearly flu vaccine and a yearly dose of your weight-loss ...